107 related articles for article (PubMed ID: 11157999)
1. Pathogenesis of Graves' ophthalmopathy--current understanding.
Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2001 Feb; 86(2):501-3. PubMed ID: 11157999
[No Abstract] [Full Text] [Related]
2. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
3. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease.
Bahn RS
J Clin Endocrinol Metab; 2003 May; 88(5):1939-46. PubMed ID: 12727937
[No Abstract] [Full Text] [Related]
4. TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.
Nagayama Y; Saitoh O; McLachlan SM; Rapoport B; Kano H; Kumazawa Y
Clin Exp Immunol; 2004 Dec; 138(3):417-22. PubMed ID: 15544617
[TBL] [Abstract][Full Text] [Related]
5. Hyperthyroid monkeys: a nonhuman primate model of experimental Graves' disease.
Wang Y; Wu LP; Fu J; Lv HJ; Guan XY; Xu L; Chen P; Gao CQ; Hou P; Ji MJ; Shi BY
J Endocrinol; 2013 Dec; 219(3):183-93. PubMed ID: 24029729
[TBL] [Abstract][Full Text] [Related]
6. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism.
Land KJ; Moll JS; Kaplan MH; Seetharamaiah GS
Endocrinology; 2004 Aug; 145(8):3724-30. PubMed ID: 15117875
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of Graves' ophthalmopathy.
Bahn RS; Heufelder AE
N Engl J Med; 1993 Nov; 329(20):1468-75. PubMed ID: 8413459
[No Abstract] [Full Text] [Related]
8. Graves' disease: the T(H)1/T(H)2 paradigm versus the "hygiene" hypothesis and defective immune regulation.
McLachlan SM
Thyroid; 2003 Feb; 13(2):127-8. PubMed ID: 12699602
[No Abstract] [Full Text] [Related]
9. Insight into Graves' hyperthyroidism from animal models.
McLachlan SM; Nagayama Y; Rapoport B
Endocr Rev; 2005 Oct; 26(6):800-32. PubMed ID: 15827111
[TBL] [Abstract][Full Text] [Related]
10. Graves' ophthalmopathy: pathogenesis and clinical implications.
Major BJ; Busuttil BE; Frauman AG
Aust N Z J Med; 1998 Feb; 28(1):39-45. PubMed ID: 9544385
[No Abstract] [Full Text] [Related]
11. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.
Prabhakar BS; Bahn RS; Smith TJ
Endocr Rev; 2003 Dec; 24(6):802-35. PubMed ID: 14671007
[TBL] [Abstract][Full Text] [Related]
12. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress.
Heufelder AE
Eur J Endocrinol; 1995 May; 132(5):532-41. PubMed ID: 7749490
[No Abstract] [Full Text] [Related]
14. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy.
Burch HB; Sellitti D; Barnes SG; Nagy EV; Bahn RS; Burman KD
J Clin Endocrinol Metab; 1994 Jun; 78(6):1384-91. PubMed ID: 8200941
[TBL] [Abstract][Full Text] [Related]
15. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
Esfahanian F; Naimi E; Doroodgar F; Jadali Z
Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
[TBL] [Abstract][Full Text] [Related]
16. [Current understanding of pathogenesis of Graves ophthalmopathy].
Ando T; Eguchi K
Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
[TBL] [Abstract][Full Text] [Related]
17. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).
Phenekos C; Vryonidou A; Gritzapis AD; Baxevanis CN; Goula M; Papamichail M
Neuroimmunomodulation; 2004; 11(4):209-13. PubMed ID: 15249726
[TBL] [Abstract][Full Text] [Related]
18. The role of TSH receptor antibodies in the management of Graves' disease.
Matthews DC; Syed AA
Eur J Intern Med; 2011 Jun; 22(3):213-6. PubMed ID: 21570635
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and treatment of the ophthalmopathy associated with Graves' disease.
Velkeniers B; Salu P
Bull Soc Belge Ophtalmol; 1992; 245():9-14. PubMed ID: 1344754
[TBL] [Abstract][Full Text] [Related]
20. [Blockade of the renin-angiotensin-aldosterone system in Graves' disease].
García JL; Etayo BZ; Calvo JI
Endocrinol Nutr; 2009 Oct; 56(8):435-6. PubMed ID: 19959156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
